Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
The path to discovering a blockbuster drug is often unpredictable. A promising molecule might be overlooked for decades, only ...
Patients with schizophrenia are “all treated with pretty much the same medicines that work the same way,” Samit Hirawat, ...
A new type of schizophrenia drug developed by Boston biotech Karuna Therapeutics won approval from the U.S. Food and Drug ...
Chaylvin Oliveira-Kalama called his family almost every day from Halawa prison, and before he died he told his mother the ...
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Patients with schizophrenia are “all treated with pretty much the same medicines that work the same way,” Samit Hirawat, Bristol Myers Squibb’s chief medical officer, said in an interview.
A drug-taking paranoid schizophrenic has been released having admitted two street robberies, after a judge said being locked ...
In a revealing Genomic Press Interview, Professor Illana Gozes discusses her groundbreaking work on activity-dependent ...
Murder accused Wire Reddington compared himself to Jesus and claimed to have absorbed the hurt and pain of his fellow inmates ...